[go: up one dir, main page]

WO1993016099A3 - Dna sequences encoding novel growth/differentiation factors - Google Patents

Dna sequences encoding novel growth/differentiation factors Download PDF

Info

Publication number
WO1993016099A3
WO1993016099A3 PCT/EP1993/000350 EP9300350W WO9316099A3 WO 1993016099 A3 WO1993016099 A3 WO 1993016099A3 EP 9300350 W EP9300350 W EP 9300350W WO 9316099 A3 WO9316099 A3 WO 9316099A3
Authority
WO
WIPO (PCT)
Prior art keywords
dna sequences
proteins
sequences encoding
differentiation factors
encoding novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1993/000350
Other languages
French (fr)
Other versions
WO1993016099A2 (en
Inventor
Helge Neidhardt
Gertrud Hoetten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH
Original Assignee
Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP93903966A priority Critical patent/EP0625989B1/en
Priority to AT93903966T priority patent/ATE188996T1/en
Priority to DK93903966T priority patent/DK0625989T3/en
Priority to UA94085688A priority patent/UA48105C2/en
Priority to CA002129820A priority patent/CA2129820C/en
Priority to DE69327645T priority patent/DE69327645T2/en
Priority to ES93903966T priority patent/ES2141761T3/en
Priority to KR1019940702756A priority patent/KR0172186B1/en
Application filed by Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH filed Critical Biopharm Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka mbH
Priority to JP51379393A priority patent/JP3193050B2/en
Priority to AU34971/93A priority patent/AU666170C/en
Publication of WO1993016099A2 publication Critical patent/WO1993016099A2/en
Publication of WO1993016099A3 publication Critical patent/WO1993016099A3/en
Priority to US08/289,222 priority patent/US6120760A/en
Anticipated expiration legal-status Critical
Priority to US08/482,577 priority patent/US5807713A/en
Priority to US09/054,526 priority patent/US6197550B1/en
Priority to US09/901,556 priority patent/US7067637B1/en
Priority to GR20000400177T priority patent/GR3032482T3/en
Priority to US09/684,383 priority patent/US7025959B1/en
Priority to US11/105,344 priority patent/US7141239B2/en
Priority to US11/132,241 priority patent/US7129054B2/en
Priority to US11/545,480 priority patent/US20070031351A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides DNA sequences encoding novel members of the TGF-β family of proteins. The TGF-β family comprises proteins which function as growth and/or differentiation factors and which are useful in medical applications. Accordingly, the invention also describes the isolation of the above-mentioned DNA sequences, the expression of the encoded proteins, the production of said proteins and pharmaceutical compositions containing said proteins.
PCT/EP1993/000350 1992-02-12 1993-02-12 Dna sequences encoding novel growth/differentiation factors Ceased WO1993016099A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
ES93903966T ES2141761T3 (en) 1992-02-12 1993-02-12 DNA CODING SEQUENCES OF NEW GROWTH / DIFFERENTIATION FACTORS.
DK93903966T DK0625989T3 (en) 1992-02-12 1993-02-12 DNA sequences encoding novel growth / differentiation factors
UA94085688A UA48105C2 (en) 1992-02-12 1993-02-12 DNA FRAGMENT CODING THE PROTEIN OF THE FAMILY TGF-в (VERSIONS), RECOMBINANT DNA MOLECULE (VERSIONS), CELL-HOST (VERSIONS), METHOD FOR OBTAINING THE PROTEIN OF THE FAMILY TGF-в (VERSIONS), PHARMACEUTICAL COMPOSITION (VERSIONS), ANTIBODY OR AN ANTIBODY FRAGMENT (VERSIONS), CDNA MOLECULE (VERSIONS)
CA002129820A CA2129820C (en) 1992-02-12 1993-02-12 Dna sequences encoding novel growth/differentiation factors
DE69327645T DE69327645T2 (en) 1992-02-12 1993-02-12 DNA SEQUENCES CODING FOR NEW GROWTH / DIFFERENTIATION FACTORS
EP93903966A EP0625989B1 (en) 1992-02-12 1993-02-12 Dna sequences encoding novel growth/differentiation factors
AU34971/93A AU666170C (en) 1992-02-12 1993-02-12 DNA sequences encoding novel growth/differentiation factors
KR1019940702756A KR0172186B1 (en) 1992-02-12 1993-02-12 Dna sequences encoding novel growth/differentiation factors
JP51379393A JP3193050B2 (en) 1992-02-12 1993-02-12 DNA sequences encoding novel growth / differentiation factors
AT93903966T ATE188996T1 (en) 1992-02-12 1993-02-12 DNA SEQUENCES CODING FOR NOVEL GROWTH/DIFERENTATION FACTORS
US08/289,222 US6120760A (en) 1992-02-12 1994-08-12 Growth/differentiation factors of the TGF-β family
US08/482,577 US5807713A (en) 1992-02-12 1995-06-07 DNA encoding growth/differentiation factor
US09/054,526 US6197550B1 (en) 1992-02-12 1998-04-03 DNA sequences encoding growth/differentiation
US09/901,556 US7067637B1 (en) 1992-02-12 1999-09-24 Antibody or antibody fragments specific for a protein of the TGF-β family
GR20000400177T GR3032482T3 (en) 1992-02-12 2000-01-26 Dna sequences encoding novel growth/differentiation factors.
US09/684,383 US7025959B1 (en) 1992-02-12 2000-10-10 MP121, a growth/differentiation factor of the TGF-β family
US11/105,344 US7141239B2 (en) 1992-02-12 2005-04-14 Growth/differentiation factor of the TGF-β family
US11/132,241 US7129054B2 (en) 1992-02-12 2005-05-19 Antibodies to a growth/differentiation factor of the TGF-β family
US11/545,480 US20070031351A1 (en) 1992-02-12 2006-10-11 DNA sequences encoding novel growth/differentiation factors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92102324 1992-02-12
EP92102324.8 1992-02-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/289,222 Continuation-In-Part US6120760A (en) 1992-02-12 1994-08-12 Growth/differentiation factors of the TGF-β family

Publications (2)

Publication Number Publication Date
WO1993016099A2 WO1993016099A2 (en) 1993-08-19
WO1993016099A3 true WO1993016099A3 (en) 1993-09-30

Family

ID=8209321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1993/000350 Ceased WO1993016099A2 (en) 1992-02-12 1993-02-12 Dna sequences encoding novel growth/differentiation factors

Country Status (16)

Country Link
EP (1) EP0625989B1 (en)
JP (2) JP3193050B2 (en)
KR (1) KR0172186B1 (en)
AT (1) ATE188996T1 (en)
CA (1) CA2129820C (en)
CZ (2) CZ287715B6 (en)
DE (1) DE69327645T2 (en)
DK (1) DK0625989T3 (en)
ES (1) ES2141761T3 (en)
GR (1) GR3032482T3 (en)
HU (1) HU218845B (en)
NZ (1) NZ249113A (en)
PT (1) PT625989E (en)
RU (1) RU2208638C2 (en)
UA (1) UA48105C2 (en)
WO (1) WO1993016099A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984623B2 (en) 1993-12-07 2006-01-10 Genetics, Institute Institute, LLC. Tendon-inducing compositions
US7091007B2 (en) 1993-09-17 2006-08-15 Genetics Institute, Llc DNA molecules encoding BMP receptor proteins
US7189392B1 (en) 1999-10-15 2007-03-13 Genetics Institute, Llc Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins
US7217691B2 (en) 1986-07-01 2007-05-15 Genetics Institute, Llc Methods of treatment of periodontal disease
US7226587B2 (en) 2001-06-01 2007-06-05 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
US7323445B2 (en) 1999-02-01 2008-01-29 Genetics Institute, Llc Methods and compositions for healing and repair of articular cartilage
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586388B2 (en) 1988-04-08 2003-07-01 Stryker Corporation Method of using recombinant osteogenic protein to repair bone or cartilage defects
US6171584B1 (en) 1992-02-12 2001-01-09 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Method of treatment with growth/differentiation factors of the TGF-β family
DE19525416A1 (en) * 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Use of MP52 for the treatment and prevention of diseases of the nervous system
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
US7025959B1 (en) 1992-02-12 2006-04-11 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh MP121, a growth/differentiation factor of the TGF-β family
US7067637B1 (en) 1992-02-12 2006-06-27 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Antibody or antibody fragments specific for a protein of the TGF-β family
US5807713A (en) * 1992-02-12 1998-09-15 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung DNA encoding growth/differentiation factor
JP3645258B2 (en) 1993-01-12 2005-05-11 ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン Growth and differentiation factor-5
JPH09503903A (en) * 1993-07-09 1997-04-22 ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン Growth differentiation factor-6
AU688779B2 (en) * 1993-07-09 1998-03-19 Johns Hopkins University School Of Medicine, The Growth differentiation factor-7
US6764994B1 (en) 1993-08-10 2004-07-20 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Growth/differential factor of the TGF-B family
RU2246315C2 (en) * 1993-08-10 2005-02-20 Биофарм Гезелльшафт Цур Биотехнологишен Энтвиклунг Фон Фармака Мбх NEW GROWTH/DIFFERENTIATION FACTOR OF TGF-β-FAMILY AND PHARMACEUTICAL COMPOSITION
IL110589A0 (en) * 1993-08-10 1994-11-11 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF- beta family
US6027919A (en) * 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
IL114397A0 (en) * 1994-07-01 1995-10-31 Bioph Biotech Entw Pharm Gmbh Growth/differentiation factor of the TGF-beta-family
DK0770089T3 (en) * 1994-07-13 2000-10-23 Univ Johns Hopkins Med Growth differentiation factor-12
AU1120295A (en) 1994-11-07 1996-05-31 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cartilage-derived morphogenetic proteins
US5846770A (en) * 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
DE69636728D1 (en) 1995-04-19 2007-01-04 Bioph Biotech Entw Pharm Gmbh NEW PROTEIN AND METHOD FOR THE PRODUCTION THEREOF
AP856A (en) * 1995-04-19 2000-07-12 Biopharm Gmbh A novel homodimer protein used in pharmaceutical preparation for treating cartlage and bone diseases.
US5635372A (en) * 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
ATE245996T1 (en) 1995-06-05 2003-08-15 Inst Genetics Llc USE OF BONE MORPHOGENESIS PROTEINS TO HEAL AND REPAIR CONNECTIVE TISSUE ATTACHMENT
US5902785A (en) * 1995-06-06 1999-05-11 Genetics Institute, Inc. Cartilage induction by bone morphogenetic proteins
ZA966489B (en) * 1995-08-03 1997-02-26 Bioph Biotech Entw Pharm Gmbh New protein human MP52 Arg.
US5700774A (en) * 1996-03-26 1997-12-23 Genetics Institute, Inc. Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same
JPH1080273A (en) 1996-05-13 1998-03-31 Hoechst Yakuhin Kogyo Kk Monoclonal antibody for mp52
US5965403A (en) * 1996-09-18 1999-10-12 Genetics Institute, Inc. Nucleic acids encoding bone morphogenic protein-16 (BMP-16)
RS49691B (en) * 1997-01-30 2007-12-31 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh., LYOPHILIZED HUMAN MORPHOGENETIC FACTOR MP52 BONE
US20010016646A1 (en) 1998-03-20 2001-08-23 David C. Rueger Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
EP2309261A1 (en) 1997-05-30 2011-04-13 Stryker Corporation Methods for evaluating tissue morphogenesis and morphogenic activity
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
US6027917A (en) 1997-12-10 2000-02-22 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-17 and BMP-18 compositions
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE19906096A1 (en) 1999-02-13 2000-08-17 Walter Sebald Protein with a heparin-binding epitope
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
AU2002308204B9 (en) 2001-11-19 2008-06-12 Scil Technology Gmbh Device having osteoinductive and osteoconductive properties
ES2260685T3 (en) 2002-09-10 2006-11-01 Scil Technology Gmbh METALLIC IMPLANT COVERED, TO A REDUCED OXYGEN CONCENTRATION, WITH OSTEOINDUCTING PROTEIN.
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
PT1675608E (en) 2003-09-12 2007-05-31 Etex Corp Injectable calcium phosphate solid rods for delivery of osteogenic proteins
CA2558395C (en) 2004-03-10 2011-11-29 Scil Technology Gmbh Coated implants, their manufacturing and use thereof
AU2005247871A1 (en) 2004-04-27 2005-12-08 Research Development Foundation Antagonism of TGF-beta superfamily receptor signaling
CA2567405A1 (en) 2004-05-25 2005-12-08 Stryker Corporation Use of morphogenic proteins for treating cartilage defects
US20060069008A1 (en) 2004-09-28 2006-03-30 Sanjay Mistry Treatment of neurological deficits in the striatum or substanta nigra pars compacta
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US7799754B2 (en) 2004-10-14 2010-09-21 Biomimetic Therapeutics, Inc. Compositions and methods for treating bone
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
EP2035030A2 (en) 2006-05-17 2009-03-18 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
EP3381463A1 (en) 2006-06-30 2018-10-03 BioMimetic Therapeutics, LLC Pdgf-biomatrix compositions and methods for treating rotator cuff injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US8524265B2 (en) 2006-08-17 2013-09-03 Warsaw Orthopedic, Inc. Medical implant sheets useful for tissue regeneration
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
WO2008082563A2 (en) 2006-12-21 2008-07-10 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
PL2121142T3 (en) * 2007-01-25 2013-09-30 Biopharm Ges Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of gdf-5 for the improvement or maintenance of dermal appearance
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
WO2009020744A1 (en) 2007-08-07 2009-02-12 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations comprising gdf-5 in aqueous acidic solution
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
WO2009102966A2 (en) 2008-02-13 2009-08-20 Keith Hruska Method of treating vascular sclerosis
EP2276458A1 (en) 2008-04-14 2011-01-26 Advanced Technologies and Regenerative Medicine, LLC Liquid buffered gdf-5 formulations
NZ591338A (en) 2008-09-09 2013-02-22 Biomimetic Therapeutics Inc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
SG2014010680A (en) 2009-02-12 2014-04-28 Stryker Corp Peripheral administration of proteins including tgf-beta superfamily members for treatment of systemic disorders and disease
AU2010213591B2 (en) 2009-02-12 2013-11-21 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including TGF-beta superfamily members
WO2010110974A1 (en) 2009-03-24 2010-09-30 Stryker Corporation Methods and compositions for tissue engineering
US8609127B2 (en) 2009-04-03 2013-12-17 Warsaw Orthopedic, Inc. Medical implant with bioactive material and method of making the medical implant
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
US20110224138A1 (en) 2009-09-09 2011-09-15 Julie Krop Methods for treating pain induced by injuries and diseases of an articular joint
US20110224410A1 (en) 2009-09-17 2011-09-15 Hile David Buffers for Controlling the pH of Bone Morphogenetic Proteins
JP2013514811A (en) 2009-12-22 2013-05-02 ストライカー コーポレイション BMP-7 mutant with reduced immunogenicity
WO2011103598A1 (en) 2010-02-22 2011-08-25 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
CA2806143A1 (en) 2010-07-30 2012-02-02 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mb H Drug delivery devices and growth factor formulations for accelerated wound healing
EP2537538A1 (en) 2011-06-22 2012-12-26 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH Bioresorbable Wound Dressing
WO2014012101A1 (en) 2012-07-13 2014-01-16 Trustees Of Tufts College Silk powder compaction for production of constructs with high mechanical strength and stiffness
WO2017075055A1 (en) 2015-10-26 2017-05-04 President And Fellows Of Harvard College Reduced and oxidized polysaccharides and methods of use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000205A1 (en) * 1986-07-01 1988-01-14 Genetics Institute, Inc. Novel osteoinductive compositions
EP0290012A1 (en) * 1987-05-04 1988-11-09 Oncogen TGF-B2 and novel compositions having anti-neoplastic activity
EP0376785A2 (en) * 1988-12-16 1990-07-04 Oncogen Limited Partnership Cloning and expression of transforming growth factor beta 2
WO1990014360A1 (en) * 1989-05-17 1990-11-29 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
EP0405376A2 (en) * 1989-06-24 1991-01-02 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Typing of human rhinoviruses
EP0416578A2 (en) * 1989-09-06 1991-03-13 Takeda Chemical Industries, Ltd. Protein, DNA and use thereof
WO1991005802A1 (en) * 1989-10-17 1991-05-02 Creative Biomolecules, Inc. Osteogenic devices

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000205A1 (en) * 1986-07-01 1988-01-14 Genetics Institute, Inc. Novel osteoinductive compositions
EP0290012A1 (en) * 1987-05-04 1988-11-09 Oncogen TGF-B2 and novel compositions having anti-neoplastic activity
EP0376785A2 (en) * 1988-12-16 1990-07-04 Oncogen Limited Partnership Cloning and expression of transforming growth factor beta 2
WO1990014360A1 (en) * 1989-05-17 1990-11-29 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
EP0405376A2 (en) * 1989-06-24 1991-01-02 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Typing of human rhinoviruses
EP0416578A2 (en) * 1989-09-06 1991-03-13 Takeda Chemical Industries, Ltd. Protein, DNA and use thereof
WO1991005802A1 (en) * 1989-10-17 1991-05-02 Creative Biomolecules, Inc. Osteogenic devices

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 9149, Derwent Publications Ltd., London, GB; AN 91-356544[49] & JP,A,3 147 787 (TAKARA SHUZO KK) 24 June 1991 see abstract *
SAMBROOK J. ET AL. 'Molecular cloning -a laboratory manual' 1989 , COLD SPRING HARBOR LABORATORY PRESS , COLD SPRING HARBOR US cited in the application *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217691B2 (en) 1986-07-01 2007-05-15 Genetics Institute, Llc Methods of treatment of periodontal disease
US7300772B2 (en) 1986-07-01 2007-11-27 Genetics Institute, Llc BMP products
US7091007B2 (en) 1993-09-17 2006-08-15 Genetics Institute, Llc DNA molecules encoding BMP receptor proteins
US6984623B2 (en) 1993-12-07 2006-01-10 Genetics, Institute Institute, LLC. Tendon-inducing compositions
US7365052B2 (en) 1993-12-07 2008-04-29 Genetics Institute, Llc. Tendon-inducing methods
US7323445B2 (en) 1999-02-01 2008-01-29 Genetics Institute, Llc Methods and compositions for healing and repair of articular cartilage
US7189392B1 (en) 1999-10-15 2007-03-13 Genetics Institute, Llc Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins
US7226587B2 (en) 2001-06-01 2007-06-05 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor

Also Published As

Publication number Publication date
EP0625989B1 (en) 2000-01-19
ES2141761T3 (en) 2000-04-01
DE69327645T2 (en) 2000-09-07
CA2129820A1 (en) 1993-08-19
CA2129820C (en) 2003-06-17
RU94046367A (en) 1997-03-27
HU9402143D0 (en) 1994-09-28
JP3193050B2 (en) 2001-07-30
AU3497193A (en) 1993-09-03
UA48105C2 (en) 2002-08-15
DK0625989T3 (en) 2000-06-26
CZ287715B6 (en) 2001-01-17
JPH07503847A (en) 1995-04-27
CZ287810B6 (en) 2001-02-14
KR950700331A (en) 1995-01-16
HUT67683A (en) 1995-04-28
GR3032482T3 (en) 2000-05-31
KR0172186B1 (en) 1999-02-01
NZ249113A (en) 1996-07-26
CZ194294A3 (en) 1995-10-18
JPH09182593A (en) 1997-07-15
JP3493105B2 (en) 2004-02-03
RU2208638C2 (en) 2003-07-20
ATE188996T1 (en) 2000-02-15
EP0625989A1 (en) 1994-11-30
WO1993016099A2 (en) 1993-08-19
PT625989E (en) 2000-06-30
DE69327645D1 (en) 2000-02-24
AU666170B2 (en) 1996-02-01
HU218845B (en) 2000-12-28

Similar Documents

Publication Publication Date Title
WO1993016099A3 (en) Dna sequences encoding novel growth/differentiation factors
IL110589A0 (en) Growth/differentiation factor of the TGF- beta family
EP1013760A3 (en) Stable bactericidal/permeabilityincreasing protein products and pharmaceutical compositions containing the same
WO1994001548A3 (en) Human nucleic acid fragments, isolated from brain adrenal tissue, placenta or bone narrow
EP1903112A3 (en) Activin receptors-like kinase(alk), belonging to the TGF receptor family and/or to the BMP receptor family
WO1994011503A3 (en) Chimeric factor viii
AU4833897A (en) Glial mitogenic factors, their preparation and use
WO2000044928A3 (en) Materials and methods for the purification of polyelectrolytes
WO1993023434A3 (en) Bpi-immunoglobulin fusion proteins
IE960853L (en) Vascular anticoagulant proteins
WO1994005791A3 (en) Dorsal tissue affecting factor and compositions
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
ATE113982T1 (en) BRANCHING ENZYME AND ITS USE.
AU7001994A (en) Mutant polypeptide of protein kinase c, nucleic acid sequences coding for said polypeptide and use thereof
MX9806041A (en) PURIFIED SR-p70 PROTEIN.
EP1947109A3 (en) Biologically active peptides
AU4609693A (en) An interferon-alpha/beta binding protein its preparation and pharmaceutical compositions containing it
WO2001053453A8 (en) Novel bone marrow nucleic acids and polypeptides
WO1998024896A3 (en) Muteins of obese protein
AU6363999A (en) Treatment of trauma (i.e. graft rejection) with liposomes containing dna encoding for ctla4ig or for anti-cd40l
WO2001092468A3 (en) Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof
WO1990003394A3 (en) New limphokines, dna sequences coding for said limphokines and pharmaceutical compositions containing said limphokines
EP0832972A3 (en) Cloning, expression and production of tasty peptides
WO2003025004A3 (en) Purified bacterial polypeptides involved in nucleic acid processing
EP0900844A3 (en) Membrane protein of Staphylococcus aureus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 249113

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2129820

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993903966

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PV1994-1942

Country of ref document: CZ

Ref document number: 1019940702756

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 08289222

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1993903966

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1997-1069

Country of ref document: CZ

Ref document number: PV1994-1942

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PV1997-1069

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 1998 54526

Country of ref document: US

Date of ref document: 19980403

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 1993903966

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV1994-1942

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV1997-1069

Country of ref document: CZ